These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19752336)

  • 1. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
    Kaumaya PT; Foy KC; Garrett J; Rawale SV; Vicari D; Thurmond JM; Lamb T; Mani A; Kane Y; Balint CR; Chalupa D; Otterson GA; Shapiro CL; Fowler JM; Grever MR; Bekaii-Saab TS; Carson WE
    J Clin Oncol; 2009 Nov; 27(31):5270-7. PubMed ID: 19752336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors.
    Bekaii-Saab T; Wesolowski R; Ahn DH; Wu C; Mortazavi A; Lustberg M; Ramaswamy B; Fowler J; Wei L; Overholser J; Kaumaya PTP
    Clin Cancer Res; 2019 Jun; 25(12):3495-3507. PubMed ID: 30804020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
    Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
    Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
    Dakappagari NK; Pyles J; Parihar R; Carson WE; Young DC; Kaumaya PT
    J Immunol; 2003 Apr; 170(8):4242-53. PubMed ID: 12682258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico design of discontinuous peptides representative of B and T-cell epitopes from HER2-ECD as potential novel cancer peptide vaccines.
    Manijeh M; Mehrnaz K; Violaine M; Hassan M; Abbas J; Mohammad R
    Asian Pac J Cancer Prev; 2013; 14(10):5973-81. PubMed ID: 24289611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitrated T helper cell epitopes enhance the immunogenicity of HER2 vaccine and induce anti-tumor immunity.
    Tian H; He Y; Song X; Jiang L; Luo J; Xu Y; Zhang W; Gao X; Yao W
    Cancer Lett; 2018 Aug; 430():79-87. PubMed ID: 29778570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer-Results from Phase Ib Trial IMU.ACS.001.
    Wiedermann U; Garner-Spitzer E; Chao Y; Maglakelidze M; Bulat I; Dechaphunkul A; Arpornwirat W; Charoentum C; Yen CJ; Yau TC; Tanasanvimon S; Maneechavakajorn J; Sookprasert A; Bai LY; Chou WC; Ungtrakul T; Drinic M; Tobias J; Zielinski CC; Chong L; Ede NJ; Marino MT; Good AJ
    Clin Cancer Res; 2021 Jul; 27(13):3649-3660. PubMed ID: 33879458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR).
    Zhu L; Zhao L; Wu M; Chen Z; Li H
    Immunol Lett; 2013 Jun; 153(1-2):33-40. PubMed ID: 23871733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
    Xu M; Kallinteris NL; von Hofe E
    Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study.
    Wiedermann U; Wiltschke C; Jasinska J; Kundi M; Zurbriggen R; Garner-Spitzer E; Bartsch R; Steger G; Pehamberger H; Scheiner O; Zielinski CC
    Breast Cancer Res Treat; 2010 Feb; 119(3):673-83. PubMed ID: 20092022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine.
    Xiang SD; Gao Q; Wilson KL; Heyerick A; Plebanski M
    Vaccine; 2015 Nov; 33(44):5950-9. PubMed ID: 26263201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer.
    Mahdavi M; Keyhanfar M; Jafarian A; Mohabatkar H; Rabbani M
    Tumour Biol; 2014 Dec; 35(12):12049-57. PubMed ID: 25142233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.
    Kaumaya PT
    Hum Vaccin Immunother; 2015; 11(6):1368-86. PubMed ID: 25874884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
    Park JW; Melisko ME; Esserman LJ; Jones LA; Wollan JB; Sims R
    J Clin Oncol; 2007 Aug; 25(24):3680-7. PubMed ID: 17704416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide.
    Tobias J; Jasinska J; Baier K; Kundi M; Ede N; Zielinski C; Wiedermann U
    BMC Cancer; 2017 Feb; 17(1):118. PubMed ID: 28183282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.
    Lennerz V; Gross S; Gallerani E; Sessa C; Mach N; Boehm S; Hess D; von Boehmer L; Knuth A; Ochsenbein AF; Gnad-Vogt U; Zieschang J; Forssmann U; Woelfel T; Kaempgen E
    Cancer Immunol Immunother; 2014 Apr; 63(4):381-94. PubMed ID: 24487961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
    Barve M; Bender J; Senzer N; Cunningham C; Greco FA; McCune D; Steis R; Khong H; Richards D; Stephenson J; Ganesa P; Nemunaitis J; Ishioka G; Pappen B; Nemunaitis M; Morse M; Mills B; Maples PB; Sherman J; Nemunaitis JJ
    J Clin Oncol; 2008 Sep; 26(27):4418-25. PubMed ID: 18802154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.
    Kobayashi H; Wood M; Song Y; Appella E; Celis E
    Cancer Res; 2000 Sep; 60(18):5228-36. PubMed ID: 11016652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide.
    Agadjanyan MG; Ghochikyan A; Petrushina I; Vasilevko V; Movsesyan N; Mkrtichyan M; Saing T; Cribbs DH
    J Immunol; 2005 Feb; 174(3):1580-6. PubMed ID: 15661919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.
    Dakappagari NK; Lute KD; Rawale S; Steele JT; Allen SD; Phillips G; Reilly RT; Kaumaya PT
    J Biol Chem; 2005 Jan; 280(1):54-63. PubMed ID: 15507452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.